国际血栓与止血学会科学标准化委员会关于脓毒症诱导凝血病在脓毒症管理中的通讯
该通讯由国际血栓与止血学会(ISTH)科学标准化委员会发布,回顾了脓毒症诱导凝血病(SIC)评分系统的应用。SIC评分于2019年推出,专门用于检测脓毒症中DIC的代偿期,该期可随疾病进展为显性DIC。过去5年研究显示SIC发生率约60%,是显性DIC的两倍,几乎所有显性DIC患者早期均符合SIC诊断;SIC死亡率≥30%,可用于抗凝治疗患者选择。尽管部分研究提示抗凝治疗可能有效,但肝素、抗凝血酶和血栓调节蛋白均未被稳健证据证实有效,需未来试验验证。
要点
- SIC评分系统于2019年由ISTH科学标准化委员会推出,专门用于检测脓毒症中DIC的代偿期,该期可进展为显性DIC。
- 脓毒症患者中SIC发生率约60%,是显性DIC发生率的两倍;几乎所有显性DIC患者早期均符合SIC诊断。
- SIC患者死亡率≥30%,SIC评分可用于筛选适合抗凝治疗的患者。
- 肝素、抗凝血酶和血栓调节蛋白是抗凝治疗的候选药物,但均未被稳健证据证实有效,需未来试验验证。
适用人群与场景
- 脓毒症患者,用于检测DIC的代偿期(SIC),该期可随疾病进展为显性DIC。
诊断标准与关键阈值
- ISTH于2001年发布显性DIC诊断标准,作为DIC失代偿期的全球标准。
- SIC评分系统于2019年推出,专门用于检测脓毒症中DIC的代偿期。
处置流程与药物剂量
- 肝素、抗凝血酶和血栓调节蛋白是SIC患者抗凝治疗的候选药物,但均未被稳健证据证实有效,未来试验 warranted。
研究设计与关键结果
- 过去5年研究报道SIC评分系统具有实用性;脓毒症患者中SIC发生率约60%,是显性DIC的两倍;几乎所有显性DIC患者早期均符合SIC诊断;SIC死亡率≥30%。
证据类型、等级与局限
- 证据类型:ISTH科学标准化委员会通讯(指南类文件)。
- 局限:原文未报告局限性。
对床旁实践的改变
- SIC评分可用于脓毒症患者中识别DIC代偿期,并筛选适合抗凝治疗的患者;但肝素、抗凝血酶和血栓调节蛋白均未被稳健证据证实有效,作者认为需未来试验验证。
指南或共识出处
- 国际血栓与止血学会(ISTH)科学标准化委员会通讯,发表于J Thromb Haemost。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Disseminated intravascular coagulation (DIC) is a life-threatening complication in sepsis and other critical conditions. The International Society on Thrombosis and Haemostasis (ISTH) released the diagnostic criteria for overt DIC in 2001. Since then, ISTH overt DIC has been used as the global standard criterion for a decompensated stage of DIC. Because detecting an earlier stage of DIC would be useful for therapeutic considerations, the scientific standardization committees of the ISTH introduced the sepsis-induced coagulopathy (SIC) scoring system in 2019. The SIC scoring system is specifically designed to detect the compensated phase of DIC in sepsis, which can lead to overt DIC with disease progression. Studies examining the performance of the SIC scoring system have reported its usefulness over the past 5 years. The reported incidence of SIC was approximately 60% in patients with sepsis, which was twice as much as that of overt DIC. Almost all patients with overt DIC were diagnosed with SIC earlier. The reported mortality of SIC was ≥30% and, thus, can be used for patient selection for anticoagulant therapy. Despite the limited data, some continue to suggest the potential efficacy of anticoagulant therapy in patients with SIC. Although heparin, antithrombin, and thrombomodulin are the candidates for anticoagulation, none of them have proven to be effective with robust evidence, and future trials are warranted.
参考来源
- Iba T, Levi M, Thachil J, et al. Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on sepsis-induced coagulopathy in the management of sepsis. J Thromb Haemost. 2022. PMID: 36695377. doi:10.1016/j.jtha.2022.10.022
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。